Guardant Health (NASDAQ:GH - Free Report) had its target price upped by Canaccord Genuity Group from $42.00 to $60.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a buy rating on the stock.
Several other brokerages have also commented on GH. JPMorgan Chase & Co. boosted their price target on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Guggenheim reissued a "buy" rating on shares of Guardant Health in a research note on Wednesday, January 22nd. The Goldman Sachs Group raised their price target on shares of Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Sanford C. Bernstein cut their price objective on Guardant Health from $40.00 to $35.00 and set an "outperform" rating for the company in a research note on Wednesday, October 30th. Finally, Raymond James reissued an "outperform" rating and set a $59.00 target price (up previously from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Nineteen analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $48.21.
View Our Latest Stock Report on GH
Guardant Health Trading Down 2.5 %
GH traded down $1.08 on Monday, reaching $42.11. The stock had a trading volume of 1,642,374 shares, compared to its average volume of 2,540,628. The business's 50-day moving average price is $40.87 and its two-hundred day moving average price is $31.89. The company has a market cap of $5.20 billion, a P/E ratio of -11.83 and a beta of 1.32. Guardant Health has a 12-month low of $15.81 and a 12-month high of $50.89.
Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The business had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. As a group, analysts predict that Guardant Health will post -2.9 earnings per share for the current year.
Insider Transactions at Guardant Health
In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the business's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the sale, the director now owns 2,676 shares of the company's stock, valued at $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders have sold 2,768 shares of company stock worth $98,798. 5.50% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Guardant Health
Hedge funds have recently bought and sold shares of the company. Polar Asset Management Partners Inc. lifted its holdings in Guardant Health by 1,902.2% during the 4th quarter. Polar Asset Management Partners Inc. now owns 454,500 shares of the company's stock worth $13,885,000 after buying an additional 431,800 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Guardant Health during the fourth quarter worth $79,000. Twinbeech Capital LP acquired a new stake in shares of Guardant Health in the fourth quarter valued at $367,000. Two Sigma Advisers LP boosted its holdings in Guardant Health by 96.7% in the fourth quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company's stock valued at $70,742,000 after purchasing an additional 1,138,300 shares during the period. Finally, Two Sigma Investments LP boosted its holdings in Guardant Health by 38.5% in the fourth quarter. Two Sigma Investments LP now owns 1,890,714 shares of the company's stock valued at $57,761,000 after purchasing an additional 525,368 shares during the period. Institutional investors and hedge funds own 92.60% of the company's stock.
About Guardant Health
(
Get Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Further Reading
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
